Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM
This page displays financial information for Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) on TradingView, specifically focusing on its price-to-sales forward metric. The content includes an overview of the company's market data, financial health, and other related services offered by the platform. It also lists various disclaimers and copyright information from data providers.
Rhythm Pharmaceuticals announces public offering of common stock
Rhythm Pharmaceuticals has announced a public offering of its common stock. The company is making this offering to raise capital. Further details about the offering size or expected use of proceeds were not provided in this snippet.
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript
Rhythm Pharmaceuticals Inc. will discuss interim six-month Phase 2 results for Setmelanotide during an upcoming call. The transcript indicates the call will feature a presentation followed by a question-and-answer session, where participants can ask questions by pressing star 11. The event is scheduled for June 13, 2026, at 1:00 PM GMT.
RYTM - Rhythm Pharmaceuticals Inc Latest SEC Filings
This page provides the latest SEC filings and comprehensive financial data for Rhythm Pharmaceuticals Inc (RYTM). It includes key metrics such as market capitalization, income, sales, EPS, various financial ratios, and stock performance indicators. The data allows for a quick overview of the company's financial health and market activity.
Rhythm Pharmaceuticals (RYTM) CSO exercises RSUs, 2,150 shares withheld for taxes
Rhythm Pharmaceuticals' Chief Scientific Officer, Alastair Garfield, exercised 4,445 restricted stock units, converting them into common stock. Concurrently, 2,150 common shares were withheld to cover tax obligations, not representing an open-market sale. Following these transactions, Garfield directly holds 12,208 common shares and retains 8,888 unvested restricted stock units.
Rhythm Pharmaceuticals (RYTM) Could Be 21% Undervalued As Trial Data Strengthens Its Case
Rhythm Pharmaceuticals (RYTM) is showing signs of being undervalued by 21% following positive interim Phase 2 trial results for setmelanotide in Prader-Willi syndrome and encouraging data for other neuroendocrine obesity indications. The company has experienced significant stock price gains, yet its fair value, based on a narrative model, suggests further upside to $139.47 due to anticipated revenue growth and a path to profitability, despite risks like ongoing operating losses and heavy reliance on setmelanotide.
Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak
Rhythm Pharmaceuticals (RYTM) has seen its stock surge by 28% over a 12-day winning streak, increasing its market cap by $1.7 billion to $7.5 billion. Despite this impressive performance, Trefis rates the stock as "Unattractive" due to its moderate operating performance, financial condition, and very high valuation. The article also highlights RYTM's stock performance against the S&P 500 over various periods and provides key financial data for the company.
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
Rhythm Pharmaceuticals, Inc. (RYTM) received an increased price target from Canaccord analyst Whitney Ijem, following positive interim results from its Phase 2 study of setmelanotide in Prader-Willi syndrome (PWS), showing improvements in BMI and hyperphagia. The company also presented new data from its MC4R agonist programs at ENDO 2026, highlighting positive outcomes in multiple rare neuroendocrine disorders. These developments suggest potential growth for the precision medicine biopharmaceutical company.
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com
This article announces the filing of a Form 4 for Rhythm Pharmaceuticals Inc. for June 25. It appears to be a brief, auto-generated update from Investing.com, providing basic information about the regulatory filing related to the company. The content primarily serves as a placeholder for the actual Form 4 details, with the majority of the page filled with market data and navigational links.
Rhythm Pharmaceuticals Stock On Fire: Up 26% With 10-Day Winning Streak
Rhythm Pharmaceuticals (RYTM) has experienced a significant surge, with its stock climbing 26% over a 10-day winning streak, increasing its market cap by $1.5 billion to $7.4 billion. Despite its moderate operating performance, the stock is considered "Unattractive" due to its very high valuation. The article also provides a detailed comparison of RYTM's returns against the S&P 500 across various periods and highlights its recent financial metrics.
RYTM Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and analysis for Rhythm Pharmaceuticals, Inc. (RYTM) stock, including current prices, historical performance, analyst ratings, and financial metrics. It highlights RYTM's recent stock growth, future price predictions from analysts, and upcoming earnings dates. The content also covers the company's financial performance, such as revenue and net income, alongside its market capitalization and volatility.
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com
This article reports on the filing of Form 4 for Rhythm Pharmaceuticals Inc. on June 25, 2026. Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) when there is a change in beneficial ownership of a company's securities by insiders. The article provides the title and publication date without further details on the content of the Form 4.
Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs
Rhythm Pharmaceuticals director Jean Christophe reported receiving 2,324 restricted stock units and stock options for 3,691 shares with an exercise price of $107.55. Both equity awards fully vest by June 24, 2027, or the day before the 2027 annual meeting, contingent on his continued service. Additionally, he converted 4,712 previously granted restricted stock units into common stock, bringing his direct holdings to 11,712 shares.
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity
RHYTHM PHARMACEUTICALS, INC. director David W. J. McGirr reported equity compensation and an option-related share issuance. On June 24, 2026, he received 2,324 Restricted Stock Units and a stock option for 3,691 shares. He also exercised 4,712 Restricted Stock Units on June 23, 2026, increasing his direct common stock holdings to 11,712 shares. These transactions are described as routine director equity grants and RSU exercise, not open-market trading.
Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units
Lynn A. Tetreault, a director at Rhythm Pharmaceuticals (RYTM), was granted 2,324 restricted stock units (RSUs) and options for 3,691 shares with an exercise price of $107.55 on June 24, 2026. These new awards have a vesting date of June 24, 2027, or the day before the company's 2027 annual stockholder meeting, contingent on her continued board service. Additionally, on June 23, 2026, 4,712 previously granted RSUs were converted into common stock, bringing her direct holdings to 11,712 shares.
Rhythm Pharmaceuticals (NASDAQ: RYTM) holders approve directors, pay and Ernst & Young
Rhythm Pharmaceuticals announced that its stockholders approved the election of two Class III directors, David W. J. McGirr and David P. Meeker, MD, to serve until the 2029 annual meeting. Shareholders also ratified Ernst & Young LLP as the independent registered public accounting firm for 2026 and, on an advisory basis, approved the compensation for named executive officers. The Annual Meeting of Stockholders was held on June 24, 2026, with approximately 92% of eligible votes participating.
Rhythm Pharmaceuticals (RYTM) Is Up 7.9% After Promising Early PWS Data for Setmelanotide - What's Changed
Rhythm Pharmaceuticals reported promising preliminary six-month Phase 2 data for setmelanotide in Prader-Willi syndrome, showing improvements in BMI, body composition, hunger, and anxiety. This early data strengthens the investment narrative for setmelanotide beyond its current rare obesity indications, despite the company remaining unprofitable and potentially needing to raise additional capital. The company's future revenue depends on successfully translating clinical data into commercial use across multiple indications.
Rhythm Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:RYTM)
This article provides an overview of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), including its stock performance, analyst forecasts, financial actuals and estimates, and key company metrics. It highlights the stock's recent price increases, future earnings expectations, and current market capitalization, along with a 'buy' rating based on technical analysis.
Rhythm Pharmaceuticals (RYTM) director exercises options and sells 37,000 shares
Rhythm Pharmaceuticals director Lynn A. Tetreault exercised stock options to acquire 37,000 shares and subsequently sold all these shares in open-market transactions on June 22, 2026. The sales were conducted under a Rule 10b5-1 plan adopted in December 2025, with an average sale price of $100.3215 per share. Following these transactions, Tetreault directly holds 7,000 shares of common stock.
Rhythm Pharmaceuticals (RYTM) Is Up 7.9% After Promising Early PWS Data for Setmelanotide - What's Changed
Rhythm Pharmaceuticals (RYTM) saw its stock rise by 7.9% after reporting promising preliminary six-month Phase 2 data for setmelanotide in Prader-Willi syndrome (PWS). The data indicated improvements in BMI, body composition, hyperphagia, and anxiety-related behaviors, with a favorable safety profile. This early success in a difficult-to-treat population could broaden the perceived long-term potential of setmelanotide beyond its current rare obesity indications, although the company remains unprofitable and may need to raise additional capital.
Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative
Rhythm Pharmaceuticals (RYTM) is under investor scrutiny, with its stock closing at $96.79 and a valuation narrative suggesting it's 30.6% undervalued with a fair value of $139.47 per share. The biopharmaceutical company, focusing on rare neuroendocrine diseases, shows strong revenue growth (38.46%) but reported a net loss of $207.84 million. While future growth is anticipated from new indications for setmelanotide, its high P/S ratio of 30.5x compared to industry averages raises questions about its current valuation.
[144] RHYTHM PHARMACEUTICALS, INC. SEC Filing
This article details a Form 144 SEC filing by Rhythm Pharmaceuticals, Inc. (RYTM) concerning a proposed sale of 37,000 shares of common stock by an individual, acquired through the exercise of stock options. The filing indicates the aggregate market value of these shares is $3,581,230.00 and they are slated for sale on NASDAQ on June 22, 2026.
Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative
Rhythm Pharmaceuticals (RYTM) is deemed 30.6% undervalued with a fair value of $139.47 per share, significantly higher than its current trading price of $96.79. This valuation is driven by expectations of rapid revenue growth and potential regulatory approvals for its drug, setmelanotide, in new indications. However, the company faces risks including ongoing operating losses and a high Price-to-Sales (P/S) ratio compared to industry peers.
Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative
Rhythm Pharmaceuticals (RYTM) is considered 30.6% undervalued, with a fair value estimated at $139.47 per share compared to its last close of $96.79. This valuation is driven by expectations of significant revenue growth and profit margin improvements from new regulatory approvals and expansions for its drug, setmelanotide. However, the company still faces risks including ongoing operating losses and a high P/S ratio compared to its peers.
Rhythm Pharmaceuticals (NasdaqGM:RYTM) Stock Forecast & Analyst Predictions
Rhythm Pharmaceuticals (RYTM) is projected to grow earnings by 65.9% and revenue by 38.5% annually, with EPS expected to increase by 66.3% per year. The company's lead asset, IMCIVREE (setmelanotide), has received expanded marketing authorizations for patients with rare genetic obesity disorders, including hypothalamic obesity and Prader-Willi syndrome, and is progressing with clinical trials for new indications and next-generation MC4R agonists. Despite positive clinical developments and revenue growth, the company is currently unprofitable and faces risks associated with ongoing clinical development and market competition.
Rhythm Pharmaceuticals Inc (RYTM) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Rhythm Pharmaceuticals Inc's (RYTM) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no record of historical stock splits. The page also presents current stock price information and market capitalization for RYTM.
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome - Slideshow (NASDAQ:RYTM) 2026-06-17
Rhythm Pharmaceuticals, Inc. discussed positive interim results from its Phase 2 Setmelanotide trial for Prader-Willi Syndrome. The company released a slide deck related to this event. This article was created by Seeking Alpha's transcripts team.
RYTM Stock Climbs As PWS Data Drive Analyst Upgrades
Rhythm Pharmaceuticals (RYTM) stock has surged by 6.9% following positive Phase 2 clinical trial results for its obesity drug in Prader–Willi syndrome (PWS) and other rare obesity indications. Analyst firms Canaccord and Wells Fargo have responded by raising their price targets to $151 and $155 respectively, citing de-risked Phase 3 trials and an undervalued PWS market opportunity. This momentum underscores RYTM's transition from a niche rare-disease company to a maturing platform with significant growth potential, driven by strong clinical data and expanding commercial reach.
Rhythm Pharmaceuticals Inc (RYTM) Earnings Forecast: Future EPS & Revenue Growth Estimates
Rhythm Pharmaceuticals Inc (RYTM) has an earnings forecast score of 8.63, ranking 24th in the Pharmaceuticals industry, with an average price target of $127.00. Based on 16 analysts, the stock has a strong "Buy" rating with an expected upside of 55.45%. The company's expected revenue for the next quarter is $68.52 million, and EPS for the next quarter is projected at $-0.83.
How New Prader‑Willi Phase 2 Setmelanotide Data At Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story
Rhythm Pharmaceuticals recently announced positive preliminary Phase 2 data for setmelanotide in Prader-Willi syndrome, showing improvements in BMI, hyperphagia, and anxiety, while preserving lean mass. This data strengthens the investment case for setmelanotide beyond its current rare obesity labels, despite the company's ongoing losses and reliance on a single lead asset. Investors are still advised to consider the risks associated with this reliance and varying fair value estimates for the stock.
How New Prader‑Willi Phase 2 Setmelanotide Data At Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story
Rhythm Pharmaceuticals' preliminary Phase 2 data for setmelanotide in Prader-Willi syndrome showed promising results, including BMI reductions and improved hyperphagia, reinforcing the drug's potential beyond current rare obesity labels. While this strengthens the long-term investment case by suggesting label expansion, the company still faces near-term challenges like commercial execution and its heavy reliance on setmelanotide as a single asset. Investors are encouraged to consider the broad range of fair value estimates and the company's financial forecasts, which project significant revenue and earnings growth by 2029.
Rhythm Pharmaceuticals: Buy Rating Reaffirmed as Strong PWS Data Lift 2033 Outlook and Price Target Raised to $151 from $143
Canaccord Genuity analyst Whitney Ijem has reiterated a Buy rating on Rhythm Pharmaceuticals, increasing the price target to $151 from $143. This optimistic outlook is driven by positive Phase 2 data for setmelanotide in Prader-Willi syndrome, showing improved BMI, fat mass reduction, and quality of life. The strong clinical profile and expanding commercial opportunity support a robust 2033 revenue forecast of $2.5 billion for the PWS program.
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
Rhythm Pharmaceuticals announced new data presentations at ENDO 2026 detailing the efficacy of its MC4R agonists, setmelanotide and bivamelagon, in treating rare neuroendocrine diseases. The findings highlight significant and sustained weight loss, BMI reductions, and improvements in hyperphagia and healthcare utilization for patients with acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS), and Prader-Willi Syndrome (PWS). These presentations underscore the potential of these treatments to improve outcomes for patients with limited therapeutic options.
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
Rhythm Pharmaceuticals (NASDAQ: RGPX) announced long-term data for its therapies setmelanotide and bivamelagon in patients with acquired hypothalamic obesity. Setmelanotide showed robust, sustained, and clinically significant weight loss over 2.5 years, while bivamelagon achieved progressive reductions in BMI and hunger over one year. The data highlight the durability of effect for setmelanotide and promising early results for bivamelagon, addressing an important aspect for therapies treating chronic conditions.
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
Rhythm Pharmaceuticals reported positive long-term data for its therapies, setmelanotide and bivamelagon, in treating acquired hypothalamic obesity. Setmelanotide demonstrated robust, sustained, and clinically significant weight loss over 2.5 years, while bivamelagon showed progressive reductions in BMI and hunger at one year. The company focuses on rare genetic and acquired diseases impacting the melanocortin pathway, which regulates hunger and body weight.
Rhythm builds case for Phase III in Prader-Willi
Rhythm Pharmaceuticals is moving towards Phase III development for its MC4R agonist Imcivree in treating Prader-Willi syndrome, based on positive six-month Phase II interim analysis results. The data indicated improvements in weight, body composition, hyperphagia, and behavioral measures in patients. This development comes as other companies, Elicio and Neumora, faced clinical setbacks in their respective therapeutic areas.
Rhythm Showcases Positive Setmelanotide Data Across Obesity Trials
Rhythm Pharmaceuticals presented positive interim Phase 2 data for setmelanotide in Prader-Willi syndrome, showing improvements in weight, hyperphagia, and anxiety, with plans to advance to Phase 3. Additional data from ENDO 2026 reinforced its long-term efficacy in acquired hypothalamic obesity and genetic obesities, solidifying Rhythm's position in rare obesity treatment. TipRanks' AI Analyst, Spark, rated RYTM as Neutral due to financial weakness, despite positive technical momentum and commercial execution.
How This Biotech Is Taking On Genetic Obesity — And Winning
Rhythm Pharmaceuticals' experimental drug, setmelanotide, showed promising results in reducing hunger and promoting weight loss in patients with Prader-Willi syndrome, a genetic form of obesity. This marks the biotech's second successful venture into genetically-linked obesity treatments, following approval for acquired hypothalamic obesity. The news caused Rhythm Pharmaceuticals' stock to surge.
Rhythm trial finds up to 38% BMI drop in complex rare obesity cases
Rhythm Pharmaceuticals (RYTM) presented new data at ENDO 2026 for its MC4R agonists, setmelanotide and oral bivamelagon, showing significant BMI reductions in patients with acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS), and Prader-Willi syndrome (PWS). Key findings include an 18.9% mean BMI reduction with setmelanotide in HO over 2.5 years and up to a 16.6% mean BMI reduction with oral bivamelagon in HO at 52 weeks. The data also highlighted weight category improvements, real-world weight loss in BBS patients, and sustained reductions in hyperphagia symptoms.
Rhythm Pharmaceuticals (RYTM) reports strong MC4R obesity data across PWS, HO and BBS at ENDO 2026
Rhythm Pharmaceuticals presented strong MC4R obesity data for its IMCIVREE (setmelanotide) and oral bivamelagon at ENDO 2026, showing significant improvements in Prader-Willi syndrome (PWS), acquired hypothalamic obesity (HO), and Bardet-Biedl syndrome (BBS) patients. Key findings include BMI reductions, fat mass loss, and improvements in hyperphagia and anxiety scores across these rare genetic disorders. The company also updated its PWS epidemiology estimates, highlighting a substantial target market.
Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest
Rhythm Pharmaceuticals (RYTM) recently released positive six-month interim Phase 2 data for setmelanotide in Prader-Willi syndrome, showing clinical improvements in BMI, fat mass, hyperphagia, and anxiety, and plans for Phase 3 development. Despite a 15.84% year-to-date share price drop, the stock has delivered a 40.51% total shareholder return over the past year. The company is considered undervalued with a narrative fair value of $138.20 and a DCF model suggesting $483.85, although it remains loss-making.
Rhythm Pharmaceuticals Says Six-Month Data Shows Setmelanotide Improves Multiple Endpoints In Pws
Rhythm Pharmaceuticals announced that six-month data for Setmelanotide in Prader-Willi Syndrome (PWS) patients demonstrated improvements across multiple endpoints. The news, reported by Reuters and Refinitiv, suggests positive efficacy for the drug in this patient population.
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Rhythm Pharmaceuticals announced positive interim six-month data from its Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS) at ENDO 2026. The results showed clinically meaningful reductions in BMI, fat mass, hyperphagia, and anxiety measures, reinforcing the rationale for advancing to Phase 3 development. The company will host a conference call to discuss these findings further.
Experimental PWS drug cuts body fat and hunger in small six-month trial
Rhythm Pharmaceuticals announced positive interim six-month data from a Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), showing significant reductions in BMI and fat mass, preservation of lean mass, and improved hyperphagia and anxiety. These results, presented at ENDO 2026, bolster confidence for advancing setmelanotide into Phase 3 development for PWS. The drug demonstrated a favorable safety profile consistent with previous observations.
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Rhythm Pharmaceuticals announced it will host a live conference call and webcast on Saturday, June 13, 2026, at 9:00 a.m. ET to discuss interim six-month results from its Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS). The CEO, David Meeker, M.D., will be joined by Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine, to discuss the data. The company is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases.
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Rhythm Pharmaceuticals (Nasdaq: RYTM) is set to announce interim six-month results from its Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS) patients. The company will host a live conference call and webcast on Saturday, June 13, at 9:00 a.m. ET to discuss the data. Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare neuroendocrine diseases, and its lead asset, IMCIVREE (setmelanotide), is approved for certain genetic forms of obesity.
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates
Rhythm Pharmaceuticals (RYTM) reported a narrower-than-expected loss in Q1, exceeding revenue estimates. The company posted a quarterly loss of $1.15 per share, which is smaller than the consensus estimate of a $1.29 loss. Revenue for the quarter reached $61 million, surpassing the Zacks Consensus Estimate of $58.12 million.
RYTM Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for Rhythm Pharmaceuticals Inc (RYTM), indicating a "Strong Sell" consensus based on various indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and moving averages, all contributing to the bearish outlook. The stock is currently trading below its key moving averages, suggesting a long-term bearish trend.
Did Rhythm’s New Bardet-Biedl Diagnostic Algorithm Just Shift Rhythm Pharmaceuticals' (RYTM) Investment Narrative?
Rhythm Pharmaceuticals recently published an updated diagnostic algorithm for Bardet-Biedl syndrome, which could increase recognition of the rare disease and potential use of Rhythm's MC4R-pathway therapies. While this is directionally positive for long-term awareness, the company still faces ongoing losses and a high valuation, with investor focus remaining on setmelanotide execution. The article suggests this development could influence the company's investment narrative and growth assumptions, alongside other label broadenings for rare obesity conditions.
Long term debt to total assets ratio of Rhythm Pharmaceuticals, Inc. – XETR:1RV
The article provides a brief snapshot of the long-term debt to total assets ratio for Rhythm Pharmaceuticals, Inc., listed on XETR under the symbol 1RV. It presents a table with "Period," "Value," "Change," and "Change %" headers, although no actual data is populated in the table itself. The surrounding content consists primarily of website navigation, disclaimers, and links to various features and services of the platform.
